|
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Clinical research trials and Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer. Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer clinical trial. Human subjects often get the best healthcare possible for their Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer  Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
For Condition: Rectal Cancer,Colon Cancer
Status: Recruiting
Sponsor(s): San Antonio Cancer Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Oblimersen may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drugs. PURPOSE: Phase I/II trial to study the effectiveness of combining oxaliplatin, fluorouracil, and leucovorin with oblimersen in treating patients who have unresectable, metastatic, or recurrentcolorectal cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose of oblimersen when administered with oxaliplatin, fluorouracil, and leucovorin calcium in patients with advanced colorectal cancer. - Determine the quantitative and qualitative toxic effects of this regimen in these patients. - Determine the antitumor activity of this regimen in these patients. - Determine the plasma pharmacokinetics of oblimersen and oxaliplatin in patients treated with this regimen. - Determine relevant predictive biomarkers of response in patients treated with this regimen. OUTLINE: This is an open-label, phase I, dose-escalation study of oblimersen followed by a non-randomized, phase II study. - Patients receive oblimersen IV continuously on days 1-5 and 15-19; leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 6, 7, 20, and 21; and oxaliplatin IV over 2 hours on days 6 and 20. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which no more than 1 of 6 patients experiences dose-limiting toxicity. - Phase II: Up to 35 additional patients are treated as in phase I, with oblimersen at the MTD. In both phases, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed at 30 days. PROJECTED ACCRUAL: A total of 6-53 patients (6-18 patients for phase I and 12-35 patients for phase II) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed adenocarcinoma of the colon or rectum - Unresectable, metastatic, or recurrent disease - Measurable or evaluable disease (phase I) - Measurable disease (phase II) - No known brain metastases - Patients with previously treated brain metastases who are not currently receiving steroids and have a stable CT scan or MRI are eligible PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9 g/dL Hepatic - Bilirubin no greater than 1.5 mg/dL - AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present) - INR no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy) - PT/PTT no greater than 1.5 times ULN (unless currently receiving anticoagulant therapy) Renal - Creatinine normal OR - Creatinine clearance at least 60 mL/min Cardiovascular - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No history of allergic reaction to compounds of similar chemical or biologic composition to fluorouracil or oxaliplatin - No other concurrent uncontrolled medical condition that would preclude study participation - No ongoing or active infection - No psychiatric illness or social situation that would preclude study compliance - No known history of degenerative facet disease during prior fluorouracil therapy - No HIV-positive patients receiving combination antiretroviral therapy PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent epoetin alfa during course 1 - No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF) - No concurrent immunotherapy Chemotherapy - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - No prior oxaliplatin - No other concurrent chemotherapy Endocrine therapy - See Disease Characteristics Radiotherapy - At least 4 weeks since prior radiotherapy and recovered - No concurrent radiotherapy Surgery - Not specified Other - No prior oblimersen - No other concurrent investigational agents - No other concurrent antitumor therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnthonyTolcher, Study Chair, San Antonio Cancer Institute
San Antonio Cancer Institute *Recruiting*
San Antonio, Texas, 78229-3264
United States
Recruiting Anthony Tolcher 210-616-5914
Additional Information:
Study ID Numbers: CDR0000271308; NCI-5793,SACI-IDD-02-23
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055822
Other Colon Cancer Studies:
1. Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
2. Genetic Study of Young Patients With Colorectal Cancer
3. Genetic Study of Patients and Families With a History of Colorectal Cancer
4. Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
5. Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
Related Studies:
Other Colon Cancer Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
|
|
|
|
|
|
|
|
